The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
PIVOTAL is an open label, randomized, multicenter, Phase III trial evaluating Nidlegy as a neoadjuvant intralesional therapy
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
Additional data from APPRAISE ATP trial reinforce modular therapy approach
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
EBITDA before special items falls 1.3 percent to € 4.41 billion
Subscribe To Our Newsletter & Stay Updated
